Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical
 Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic
 dermatitis.
Inclusion Criteria:

 -  Males or females 2 years and older

 -  Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka

 -  Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)

 -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1

 -  All female subjects of childbearing potential must use acceptable methods of
 contraception from the Screening Visit continuously until 30 days after stopping study
 drug

 Exclusion Criteria:

 -  As determined by the study doctor, a medical history that may interfere with study
 objectives

 -  Unstable AD or any consistent requirement for high potency topical corticosteroids

 -  History of use of biologic therapy (including intravenous immunoglobulin)

 -  Recent or anticipated concomitant use of systemic or topical therapies that might
 alter the course of AD

 -  Recent or current participation in another research study

 -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the
 participation in the study

 -  Participation in a previous AN2728 clinical trial